Aethlon MedicalAEMD -10.66%23 ROA % is -104.74% as of Mar. 2026. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 857 Medical Devices & Instruments companies, Aethlon Medical ranks worse than 92.07% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Aethlon Medical's annualizedNet Income for the quarter that ended in Mar. 2026 was $-7.54 Mil.
Aethlon Medical's average Total Assets over the quarter that ended in Mar. 2026 was $7.20 Mil. Therefore, Aethlon Medical's annualized ROA % for the quarter that ended in Mar. 2026 was -104.74%.
The historical rank and industry rank for Aethlon Medical's ROA % or its related term are showing as below:
AEMD'
s ROA % Range Over the Past 10 Years
Min: -342 Med: -99.63 Max: -65.16
Current: -104
During the past 13 years, Aethlon Medical's highest ROA % was -65.16%. The lowest was -342.00%. And the median was -99.63%.
AEMD's ROA % is ranked worse than 92.07% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs AEMD: -104.00
Aethlon Medical (NAS:AEMD) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Aethlon Medical ROA % Related Terms
Aethlon Medical ROA % Historical Data
* Premium members only.
The historical data trend for Aethlon Medical's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aethlon Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's ROA % distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Aethlon Medical (AEMD) has a ROA % of -104.74% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aethlon Medical and its competitors. According to the industry distribution chart, Aethlon Medical ranks #789 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 92.1%.
Is Aethlon Medical's ROA % too high?
Aethlon Medical's current ROA % is -104.74%. Based on the distribution chart, Aethlon Medical ranks #789 out of 857 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's ROA % compare to RMSL and BTCY?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #789 out of 857 companies for ROA %. This places Aethlon Medical in the lower half of its industry. The industry median ROA % is 0.59. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Aethlon Medical and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current ROA % is -104.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current ROA % of -104.74%. The current ROA % is -104.74%. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current ROA % is -104.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score
Get the complete analysis for AEMD
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 
